SCHEMBL2660933

SCHEMBL2660933

CC(C)(C)OC(=O)N1CCC(/C=N\O)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.51
RECQL P46063 1/20 0.49
EPHX1 P07099 1/20 0.49
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GPR119 Q8TDV5 8/20 0.46
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
THRB P10828 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN6 P29350 1/20 0.45
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1106553 1.00 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2656299 1.00 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL24635924 0.91 HPGD (0.46) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL23513101 0.91 HPGD (0.46) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL23104490 0.87 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL20615615 0.86 EPHX1 (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL27200343 0.84 HPGD (0.49) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL18344916 0.83 NR1H2 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL18344914 0.83 NR1H2 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL20348739 0.83 NR1H2 (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2025-08-14 US disclosed
US-12319672-B2 Alpha-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-03 US disclosed
EP-4021904-B1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2024-01-03 EP disclosed
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2022-09-08 US disclosed
US-8431713-B2 2-aminopyridine derivatives as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2013-04-30 US disclosed
US-8362037-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2013-01-29 US disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 US disclosed
US-20100099713-A1 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2010-04-22 US disclosed
WO-2008091770-A1 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 HPGD 2961/4885RECQL 2632/4885EPHX1 4553/4885
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 HPGD 2776/4885RECQL 3706/4885EPHX1 4615/4885
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 HPGD 704/4885RECQL 2971/4885EPHX1 4374/4885
US-20100099713-A1 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 HPGD 1338/4885RECQL 1734/4885EPHX1 4604/4885
US-12319672-B2 Alpha-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 HPGD 2776/4885RECQL 3706/4885EPHX1 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.